Theorem Clinical Research, Charles River Form Alliance
Theorem Clinical Research?s alliance with Charles River Laboratories will provide nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology.
The CRO, Theorem Clinical Research has formed an alliance with the CRO, Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology to support clinical trials.
Charles River’s research models, preclinical testing capabilities and clinical support services are backed by a bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped with instrumentation to measure drug and metabolite concentrations in biological matrices and to provide support for capillary micro- sampling and dried blood spot analysis.
Source: Theorem Clinical Research
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
